Soleno Therapeutics, Inc. (FRA:6XC)
Germany
· Delayed Price · Currency is EUR 45.00
-0.04 (-0.09%)
At close: Dec 5, 2025
Soleno Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 246.66 | 87.93 | 169.68 | 14.6 | 21.3 | 49.22 | Upgrade
|
| Short-Term Investments | 252.27 | 203.51 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 498.93 | 291.44 | 169.68 | 14.6 | 21.3 | 49.22 | Upgrade
|
| Cash Growth | 94.31% | 71.76% | 1062.04% | -31.46% | -56.72% | 137.42% | Upgrade
|
| Receivables | 25.51 | - | - | - | - | - | Upgrade
|
| Inventory | 6.67 | - | - | - | - | - | Upgrade
|
| Prepaid Expenses | 3.74 | 2.45 | 1.68 | 1.05 | 1.12 | 1.02 | Upgrade
|
| Total Current Assets | 534.85 | 293.89 | 171.36 | 15.65 | 22.42 | 50.24 | Upgrade
|
| Property, Plant & Equipment | 2.46 | 2.98 | 0.42 | 0.16 | 0.45 | 0.16 | Upgrade
|
| Long-Term Investments | 57.15 | 27.21 | - | - | - | - | Upgrade
|
| Other Intangible Assets | 5.35 | 6.81 | 8.75 | 10.69 | 12.64 | 14.58 | Upgrade
|
| Other Long-Term Assets | 0.08 | 0.08 | 0.17 | - | 0.04 | - | Upgrade
|
| Total Assets | 599.9 | 330.97 | 180.69 | 26.5 | 35.55 | 64.98 | Upgrade
|
| Accounts Payable | 8.15 | 8.88 | 3.15 | 1.78 | 3.25 | 3.49 | Upgrade
|
| Accrued Expenses | 24.3 | 6.6 | 6.53 | 4.9 | 4.15 | 4.79 | Upgrade
|
| Current Portion of Leases | 0.7 | 0.53 | 0.27 | 0.16 | 0.28 | 0.15 | Upgrade
|
| Other Current Liabilities | 0.11 | 2.74 | 1.56 | 0.48 | 0.32 | 0.19 | Upgrade
|
| Total Current Liabilities | 33.25 | 18.75 | 11.51 | 7.31 | 8.01 | 8.62 | Upgrade
|
| Long-Term Debt | 49.85 | 49.83 | - | - | - | - | Upgrade
|
| Long-Term Leases | 2.11 | 2.47 | 0.13 | - | 0.18 | - | Upgrade
|
| Other Long-Term Liabilities | 19.87 | 14.81 | 11.55 | 8.84 | 9.58 | 10.82 | Upgrade
|
| Total Liabilities | 105.09 | 85.86 | 23.18 | 16.15 | 17.76 | 19.44 | Upgrade
|
| Common Stock | 0.05 | 0.05 | 0.03 | 0.01 | 0.08 | 0.08 | Upgrade
|
| Additional Paid-In Capital | 969.12 | 696.97 | 433.89 | 247.76 | 231.07 | 227.91 | Upgrade
|
| Retained Earnings | -474.73 | -452.26 | -276.41 | -237.42 | -213.36 | -182.45 | Upgrade
|
| Comprehensive Income & Other | 0.36 | 0.36 | - | - | - | - | Upgrade
|
| Total Common Equity | 494.81 | 245.11 | 157.51 | 10.35 | 17.79 | 45.55 | Upgrade
|
| Shareholders' Equity | 494.81 | 245.11 | 157.51 | 10.35 | 17.79 | 45.55 | Upgrade
|
| Total Liabilities & Equity | 599.9 | 330.97 | 180.69 | 26.5 | 35.55 | 64.98 | Upgrade
|
| Total Debt | 52.66 | 52.83 | 0.4 | 0.16 | 0.46 | 0.15 | Upgrade
|
| Net Cash (Debt) | 503.42 | 265.82 | 169.28 | 14.45 | 20.85 | 49.08 | Upgrade
|
| Net Cash Growth | 78.71% | 57.03% | 1071.72% | -30.70% | -57.52% | 142.19% | Upgrade
|
| Net Cash Per Share | 10.38 | 6.62 | 10.26 | 1.72 | 3.92 | 11.76 | Upgrade
|
| Filing Date Shares Outstanding | 53.71 | 45.86 | 32.46 | 8.17 | 5.34 | 5.31 | Upgrade
|
| Total Common Shares Outstanding | 53.7 | 45.7 | 31.68 | 8.16 | 5.32 | 5.31 | Upgrade
|
| Working Capital | 501.6 | 275.14 | 159.85 | 8.33 | 14.42 | 41.63 | Upgrade
|
| Book Value Per Share | 9.21 | 5.36 | 4.97 | 1.27 | 3.34 | 8.58 | Upgrade
|
| Tangible Book Value | 489.46 | 238.31 | 148.76 | -0.35 | 5.16 | 30.97 | Upgrade
|
| Tangible Book Value Per Share | 9.11 | 5.21 | 4.70 | -0.04 | 0.97 | 5.83 | Upgrade
|
| Machinery | - | 0.2 | 0.1 | 0.1 | 0.1 | 0.05 | Upgrade
|
| Leasehold Improvements | - | 0.05 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.